Ken J. Ishii | Director and Professor
International Vaccine Design Center, The Institute of Medical Science, The University of Tokyo

Ken J. Ishii, Director and Professor, International Vaccine Design Center, The Institute of Medical Science, The University of Tokyo

Prof. Ken J. Ishii, M.D., Ph.D., currently Director for Int. Vaccine Design Center, The Institute of Medical Science, the University of Tokyo, has 27 years of experience in Vaccine R&D since 1998 including 7 years as a IND reviewer at US Food and Drug Administration (FDA), 15 years as a basic immunologist at Osaka University, 9 years as a vaccine adjuvant expert at National Institute (NIBIOHN), 2 years as managing director at AMED (medical funding agency), as well as Advisor for G7 100 days mission IPPS, CEPI and several domestic funding agency in Japan. He has contributed to basic research on infectious diseases and immunology, resulted in numerous books and over 290 periodical publications and 42,000 citations with H-index 91 as well as over 50 patents related to vaccine and adjuvant, and to regulation of many vaccines and guidelines for vaccine preclinical and clinical trials in Japan and US.

Appearances:



Pre-Congress Workshops - Monday 30th March @ 10:00

VACCINE TECHNOLOGY WORKSHOP

Topics:

  • Cutting-edge technologies shaping the future of vaccine development.  
  • Adjuvants
  • AI tools for Protein Design/Epitopes

Workshop Chair: Dr David Burkhart, Chief Executive Officer, Inimmune

10:00 Chair’s Opening Remarks

10.10 Self-replicating RNA Platform Development

10.25 Designing the Next Generation of Vaccines: Harnessing Generative AI for In Silico Immunogen Discovery

10.40 A Versatile Platform Technology Enabling Development Of cVLP Vaccines Within Infectious and Non-Communicable Diseases

10:55 Engineering Modular Immunogen Platforms to Neutralize Evolving Chemical Threats 

11:10 A Modified Sarna Platform Technology for the Development of A Pan-Filovirus Vaccine

11:25 Killed Whole Cell Genome Reduced Bacterial Vaccines: A New Rapid, Inexpensive, Easily Manufactured, Thermostable Platform

11:40- Q&A

12:00 Panel: The Evolving Landscape of Novel Adjuvant Development – Navigating Safety, Access and Innovation

  • Safety as a priority and hurdle for the acceptance novel adjuvants
  • How can we further de-risk adjuvants?
  • Changing Models in licensing and access, how will non-exclusive licensing change the field?
  • Can innovation and adoption of new technologies overcome barriers in cost and access? 

 

Session led by: adaptvac

Day 3 - Thursday 2nd April @ 09:40

An adjuvant database for preclinical evaluation of vaccines and immunotherapeutics

last published: 11/Mar/26 19:15 GMT

back to speakers